VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback